Biogen(US:BIIB) Globenewswire·2025-11-03 12:30Core Insights - Biogen Inc. is set to present new data on felzartamab, an investigational anti-CD38 monoclonal antibody, at Kidney Week 2025, highlighting its potential in treating various kidney diseases [1][2] - The first data readout from the TRANSCEND study, focusing on adult kidney recipients with late antibody-mediated rejection, is expected in 2027 [1] Company Activities - Biogen will showcase first-of-its-kind gene expression data and evidence of preserved humoral immunity in patients with IgA nephropathy receiving felzartamab [2] - Presentations will include an oral presentation on RNAseq data from the Phase 2 IGNAZ study and a poster on the impact of felzartamab on vaccine immunity in IgAN patients [2][5] - The company will also host an Exhibitor Spotlight discussing the role of CD38+ cells in immune-mediated kidney diseases [2][5] Clinical Development - Felzartamab is currently being evaluated in three pivotal Phase 3 studies targeting late antibody-mediated rejection, IgA nephropathy, and primary membranous nephropathy [1][2] - The ongoing studies include TRANSCEND, PREVAIL, and PROMINENT, with specific presentations scheduled during the conference [6][7] Product Information - Felzartamab selectively depletes CD38+ plasma cells and is considered a potential first-in-class therapeutic candidate for various immune-mediated diseases [4][5] - The drug was originally developed by MorphoSys AG and is now exclusively licensed to Human Immunology Biosciences, which Biogen acquired in July 2024 [7] Company Overview - Biogen, founded in 1978, focuses on pioneering innovative science to deliver new medicines and create value for shareholders [8] - The company aims to leverage its understanding of human biology to advance first-in-class treatments [8]